These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8100837)

  • 1. In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules.
    Christen RD; Jekunen AP; Jones JA; Thiebaut F; Shalinsky DR; Howell SB
    J Clin Invest; 1993 Jul; 92(1):431-40. PubMed ID: 8100837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells.
    Mann SC; Andrews PA; Howell SB
    Int J Cancer; 1991 Jul; 48(6):866-72. PubMed ID: 1713575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro.
    Jekunen AP; Christen RD; Shalinsky DR; Howell SB
    Br J Cancer; 1994 Feb; 69(2):299-306. PubMed ID: 7905279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
    Andrews PA; Velury S; Mann SC; Howell SB
    Cancer Res; 1988 Jan; 48(1):68-73. PubMed ID: 3335000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
    Komuro Y; Udagawa Y; Susumu N; Aoki D; Kubota T; Nozawa S
    Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulation of cis-diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: an altered response in accumulation-defective resistant cells.
    Marverti G; Andrews PA
    Clin Cancer Res; 1996 Jun; 2(6):991-9. PubMed ID: 9816260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line.
    Naredi P; Heath DD; Enns RE; Howell SB
    Cancer Res; 1994 Dec; 54(24):6464-8. PubMed ID: 7987844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of lipid content, surface membrane fluidity, and temperature dependence of cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
    Mann SC; Andrews PA; Howell SB
    Anticancer Res; 1988; 8(6):1211-5. PubMed ID: 3218956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells.
    Andrews PA; Albright KD
    Cancer Res; 1992 Apr; 52(7):1895-901. PubMed ID: 1551118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
    Kowalski RJ; Giannakakou P; Gunasekera SP; Longley RE; Day BW; Hamel E
    Mol Pharmacol; 1997 Oct; 52(4):613-22. PubMed ID: 9380024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance.
    Zinkewich-Péotti K; Andrews PA
    Cancer Res; 1992 Apr; 52(7):1902-6. PubMed ID: 1551119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the Na+, K(+)-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells.
    Andrews PA; Mann SC; Huynh HH; Albright KD
    Cancer Res; 1991 Jul; 51(14):3677-81. PubMed ID: 1648442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin efflux, binding and intracellular pH in the HTB56 human lung adenocarcinoma cell line and the E-8/0.7 cisplatin-resistant variant.
    Chau Q; Stewart DJ
    Cancer Chemother Pharmacol; 1999; 44(3):193-202. PubMed ID: 10453720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential regulation of the cytotoxicity activity of paclitaxel by orobol and platelet derived growth factor in human ovarian carcinoma cells.
    Isonishi S; Saitou M; Saitou M; Yasuda M; Tanaka T
    Oncol Rep; 2007 Jul; 18(1):195-201. PubMed ID: 17549368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depletion of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells.
    Isonishi S; Ohkawa K; Tanaka T; Howell SB
    Br J Cancer; 2000 Jan; 82(1):34-8. PubMed ID: 10638963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha.
    Isonishi S; Jekunen AP; Hom DK; Eastman A; Edelstein PS; Thiebaut FB; Christen RD; Howell SB
    J Clin Invest; 1992 Oct; 90(4):1436-42. PubMed ID: 1401076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agents.
    Sackett DL; Giannakakou P; Poruchynsky M; Fojo A
    Cancer Chemother Pharmacol; 1997; 40(3):228-32. PubMed ID: 9219506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.
    Kavallaris M; Kuo DY; Burkhart CA; Regl DL; Norris MD; Haber M; Horwitz SB
    J Clin Invest; 1997 Sep; 100(5):1282-93. PubMed ID: 9276747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
    Mann SC; Andrews PA; Howell SB
    Cancer Chemother Pharmacol; 1990; 25(4):236-40. PubMed ID: 2295111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.